EMD Serono’s Mavenclad Edges Past Novartis’ Gilenya in the Recent Switch Segment of Canada’s Multiple Sclerosis Market, Although Brand Familiarity Remains An Addressable Barrier
EXTON, Pa., May 28, 2019 /PRNewswire/ -- Therapeutic choice for multiple sclerosis (MS) in Canada has expanded substantially over the past...